Online Surveys to Assess the Perception and Performance of Imaging and Associated Aspects
Online Surveys to Assess the Perception and Performance of Imaging Associated Aspects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43221
- Martha Morehouse Medical plaza
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female participants who have access to the online survey tool and can read and write in English
Exclusion Criteria:
- None, as this is voluntary
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Volunteer participants
Volunteer participants will participate in surveys assessing their perception of various imaging aspects.
|
The investigators are recruiting health care providers for these surveys that are involved in or use imaging.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perception of PET/CT imaging agent Y-90
Time Frame: through study completion, on average 2-5 years
|
To evaluate participants' perceptions of Y-90 using a likert scale on an online survey
|
through study completion, on average 2-5 years
|
|
Perception of PET/CT imaging agent NaF
Time Frame: through study completion, on average 2-5 years
|
To evaluate participants' perceptions of NaF using a likert scale on an online survey
|
through study completion, on average 2-5 years
|
|
Perception of MRI contrast agents
Time Frame: through study completion, on average 2-5 years
|
To evaluate participants' perceptions of MR contrast agents using a likert scale
|
through study completion, on average 2-5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael V Knopp, MD, PhD, Ohio State University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- RP0320_S02/2018E0141
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.